NHS-Galleri: All the Facts From the Huge Study of Multi-Cancer Screening With One Blood Test!
In this article
Early Detection of Multiple Cancers With a Single Blood Test: Hope or Warning?
Study design: What did NHS-Galleri test?
NHS-Galleri is the first large randomized controlled trial designed to measure whether an MCED test provides clinical benefit in population screening. It was conducted within England’s NHS among people aged 50–77 with no cancer symptoms, selected to reflect population demographics. Participants provided blood samples three times, approximately once a year.
| Item | Galleri arm | Control arm | Clinical significance |
|---|---|---|---|
| Participant profile | Ages 50–77, asymptomatic, England’s NHS population | A large population close to actual population-screening conditions. | |
| Intervention | Annual Galleri blood test + standard NHS screening | Standard NHS screening alone | The test was added to existing screening rather than replacing it. |
| Screening duration | Three blood samples, approximately 12 months apart | An annual screening approach, not a one-time test, was assessed. | |
| Primary objective | Reduce stage III–IV diagnoses across 12 prespecified cancers | Whether an MCED test genuinely reduces late-stage cancer was tested. | |
| Secondary objectives | Stage IV diagnoses, cancer detection rate, test performance, safety, and healthcare-resource use | Needed to understand the balance of practical benefit and harm. | |
MCED means “multi-cancer early detection.” Galleri looks for a cancer signal by analyzing methylation patterns in circulating cell-free DNA and, when a signal is present, tries to predict the organ of cancer origin. These tests should be considered only as an addition to existing mammography, colonoscopy, cervical screening, or lung cancer screening, not as a replacement.
Main result: The primary endpoint was not met
The study’s most important finding is this: adding Galleri did not demonstrate a statistically significant reduction in stage III–IV diagnoses across the 12 prespecified cancers. After three screening rounds, the incidence rate ratio for stage III–IV cancers was IRR 1,03 ; there was no significant decrease in the expected direction.
The reduction in stage IV diagnoses strengthened over time
The study’s most promising finding was that the reduction in stage IV cancer diagnoses increased as annual screening rounds progressed. Stage IV diagnoses fell by 9% in the first round, 22% in the second, and 26% in the third. This suggests that repeated annual MCED screening could show a more pronounced “late-stage reduction” effect over time.
The first round detects cancers already present in the population but not diagnosed; this is called prevalent screening. Subsequent rounds detect cancers newly developing or becoming detectable over time and are interpreted as incident screening.
Test performance: A positive result is meaningful; a negative result does not rule out cancer
Galleri’s technical performance has some strengths. Across three screening rounds, 1.801 participants had a positive MCED result, and 937 were diagnosed with cancer. The positive predictive value was reported as %52,0, specificity as %99,55, the false-positive rate as %0,45 , and accuracy in predicting the organ of cancer-signal origin as %92,5 .
Sensitivity, however, was limited. Of cancers diagnosed within 12 months after the blood sample, the test detected %30,7across all cancer types and, among the 12 prespecified cancer types, %54,7of cases. A negative result therefore does not mean “no cancer.”
More cancers were found, and diagnoses through emergency presentation decreased
Adding Galleri to standard screening increased screen-detected cancer numbers approximately 4-fold . Cancers presenting with clinical symptoms decreased by 21%, and cancers diagnosed through emergency presentation decreased by 25% . In addition, stage I–II diagnoses across the 12 prespecified cancers increased by 16%.
| Outcome | Data | How should it be interpreted? |
|---|---|---|
| Primary endpoint | No significant reduction in combined stage III–IV diagnoses | The study’s main objective was not met; this is the most critical finding. |
| Stage IV diagnoses | Overall reduction of 14%; 26% reduction in round 3 | Promising secondary signal; longer follow-up is needed. |
| Cancer detection | 4-fold increase in screen-detected cancers | The test can find more asymptomatic cancers. |
| Emergency presentation | 25% reduction | Noteworthy for potential benefits to patients and the health system. |
| Mortality | Not yet available | The most important data for the true value of screening are awaited. |
Critical reading: Why do these results offer both hope and a warning?
How should we read these data without exaggeration?
- The primary endpoint was negative: The objective of reducing stage III–IV cancers together was not met. This is the study’s most important scientific result.
- The stage IV reduction is promising, but a secondary endpoint: The overall reduction of 14% and the strengthening signal over the years matter, but do not replace the main objective.
- There are no mortality data: Earlier diagnosis does not always mean longer life. Lead-time bias and the risk of overdiagnosis should be considered.
- A negative test is not reassurance: Because sensitivity across all cancers is 30,7%, a negative result should not stop standard screening or symptom assessment.
- The burden on the health system matters: After a positive test, imaging, endoscopy, biopsy, and follow-up may place additional demands on diagnostic infrastructure.
- The evidence threshold for population screening should be high: For an expensive, large-scale screening program, clinical benefit, harms, cost-effectiveness, and the effect on mortality must be demonstrated together.
What does this mean for practice in Türkiye?
MCED tests will become increasingly prominent in Türkiye in the coming years. NHS-Galleri, however, does not provide sufficient evidence to introduce these tests into routine population-scale screening today. The most appropriate approach should be to strengthen existing evidence-based screening, develop risk-based screening strategies, and evaluate MCED tests in controlled, ethics-committee-approved programs that collect data.
How should this be explained to the patient?
MCED tests such as Galleri can detect some cancers before symptoms, but cannot detect every cancer, and extending life has not yet been proved. A positive result necessarily requires further investigation; a negative result does not remove the need for mammography, colonoscopy, cervical screening, lung cancer screening, or consulting a doctor if symptoms are present.
Drozdogan Academic Commentary
NHS-Galleri is the most realistic test of MCED to date, and its result should be read as “neither a complete victory nor a complete failure.”
The negative primary endpoint shows that it is too early to move to population-scale MCED screening. However, fewer stage IV diagnoses, more screen-detected cancers, and fewer diagnoses through emergency presentation suggest that the technology retains its biological and clinical potential.
The most appropriate way forward is not to replace existing screening with MCED tests, but to proceed with transparent, long-term follow-up and cost-effectiveness analyses that show whether they genuinely reduce mortality from deadly cancers lacking screening.
Conclusion
NHS-Galleri is the most important randomized study conducted to determine MCED’s role in population screening. Galleri found more cancers, showed a signal of fewer stage IV diagnoses, and reduced cancer diagnoses through emergency presentation. However, its main objective of significantly reducing stage III–IV cancers was not met.
The NHS-Galleri message is therefore balanced: MCED tests could become important future tools in early cancer detection, but today should not replace existing screening programs before a mortality benefit is demonstrated, and widespread population-level use should be approached carefully.
- ASCO 2026 LBA100. NHS-Galleri: Primary results from a randomised controlled trial to assess the clinical utility of a multi-cancer early detection test in population screening.
- GRAIL. Full results from NHS-Galleri Trial at 2026 ASCO Annual Meeting. 30 May 2026.
- ASCO Research Summary. Galleri blood test may be able to find cancer earlier than standard screening alone.
- The Guardian. Trial of multi-cancer blood test among NHS patients fails to meet main aim. 30 May 2026.
- Science Media Centre. Expert reaction to NHS-Galleri full results. 30 May 2026.
- drozdogan.com. How Close Are We to a Multi-Cancer Early Detection Test From a Single Blood Sample?
- drozdogan.com. The Challenge of Proving the Benefit of Multi-Cancer Early Detection Tests.
- drozdogan.com. What Is a Multi-Cancer Early Detection Test? What Do True, False, Positive, and Negative Results Mean?
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.